One More Big Pharma Bribery Scandal?

Big pharma company Eli Lilly faces allegations of bribing medical doctors in China, just weeks after similar claims arose against its peers and Sanofi. In the following video, taken from The Motley Fool's health-care show, analysts David Williamson and Max Macaluso discuss this story and the potential impact of these claims on investors.

Take a moment to look past these recent scandals, and you'll see that one of the best parts of owning big pharma stocks is their attractive dividends. But smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article One More Big Pharma Bribery Scandal? originally appeared on Fool.com.

David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.